SCHEMBL4514610

SCHEMBL4514610

Cc1ccc(C(=O)NCC(O)CO)cc1-n1c(C)cc(OCc2ccccc2CNC(=O)Nc2cc(C(C)(C)C)nn2-c2ccc(O)cc2)c(Cl)c1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 17/20 0.46
MAPK11 Q15759 5/20 0.40
MAPK12 P53778 4/20 0.40
MAPK13 O15264 3/20 0.40
FLT1 P17948 1/20 0.37
MINK1 Q8N4C8 1/20 0.37
CCNC P24863 1/20 0.37
CDK8 P49336 1/20 0.37
HCK P08631 1/20 0.36
MAP4K4 O95819 1/20 0.36
ABL1 P00519 1/20 0.36
NTRK1 P04629 1/20 0.36
FYN P06241 1/20 0.36
LYN P07948 1/20 0.36
RET P07949 1/20 0.36
BCR P11274 1/20 0.36
FGFR1 P11362 1/20 0.36
BRAF P15056 1/20 0.36
EPHA1 P21709 1/20 0.36
EPHA2 P29317 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4507487 0.95 MAPK14 (0.45) MAPK14MAPK11MAPK12MAPK13FLT1
SCHEMBL4507514 0.94 MAPK14 (0.44) MAPK14MAPK11MAPK12MAPK13FLT1
SCHEMBL4502295 0.92 MAPK14 (0.48) MAPK14MAPK11MAPK12MAPK13FLT1
SCHEMBL4498194 0.91 MAPK14 (0.40) MAPK14MAPK11MAPK12MAPK13FLT1
SCHEMBL4509870 0.91 MAPK14 (0.50) MAPK14MAPK11MAPK12MAPK13CCNC
SCHEMBL4500788 0.90 MAPK14 (0.48) MAPK14MAPK11MAPK12MAPK13FLT1
SCHEMBL4520752 0.90 MAPK14 (0.48) MAPK14MAPK11MAPK12MAPK13CCNC
SCHEMBL4500943 0.90 MAPK14 (0.51) MAPK14MAPK11MAPK12MAPK13CCNC
SCHEMBL4505139 0.89 MAPK14 (0.51) MAPK14MAPK11MAPK12MAPK13FLT1
SCHEMBL5132266 0.89 MAPK14 (0.43) MAPK14MAPK11MAPK12MAPK13FLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090270350-A1 Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives PFIZER INC. 2009-10-29 US claimed
EP-1987022-A1 PYRIDINONE PYRAZOLE UREA AND PYRIMIDINONE PYRAZOLE UREA DERIVATIVES Pfizer Products Inc. (US) 2008-11-05 EP claimed
WO-2007091176-A1 PYRIDINONE PYRAZOLE UREA AND PYRIMIDINONE PYRAZOLE UREA DERIVATIVES PFIZER PRODUCTS INC. (US) 2007-08-16 WO claimed
US-20090270350-A1 Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives PFIZER INC. 2009-10-29 US disclosed
US-20090270350-A1 Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives PFIZER INC. 2009-10-29 US disclosed
US-20090270350-A1 Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives PFIZER INC. 2009-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270350-A1 Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives PDXK, UMPS, CDK2 MAPK14 117/4885MAPK11 404/4885MAPK12 178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.